Table 2.
HRs and 95% CIs for overall and CRC-specific mortality according to quintiles of prediagnostic serum Se and SELENOP among CRC cases in the EPIC study.
| Selenium | Selenoprotein P | |||||
|---|---|---|---|---|---|---|
| Deaths/Total | µg/L | HR (95% CI) | Deaths/Total | mg/L | HR (95% CI) | |
| Overall mortality | ||||||
| Age-, Sex-, Stage-adjusted a | ||||||
| Quintile 1 | 103/197 | ≤67.5 | 1.00 (ref) | 109/197 | ≤3.53 | 1.00 (ref) |
| Quintile 2 | 104/201 | 67.6–77.4 | 1.07 (0.80–1.42) | 104/199 | 3.54–4.06 | 0.96 (0.72–1.28) |
| Quintile 3 | 104/198 | 77.5–88.0 | 0.91 (0.68–1.22) | 95/199 | 4.07–4.50 | 0.77 (0.57–1.02) |
| Quintile 4 | 102/199 | 88.1–99.9 | 0.91 (0.68–1.22) | 91/197 | 4.51–5.06 | 0.75 (0.56–1.00) |
| Quintile 5 | 101/198 | ≥100.0 | 0.76 (0.56–1.02) | 114/198 | ≥5.07 | 0.87 (0.65–1.15) |
| Ptrend b | 0.04 | 0.27 | ||||
| per one SD c | 514/993 | 0.91 (0.83–1.00) | 513/990 | 0.95 (0.86–1.04) | ||
| Multivariable-adjusted d | ||||||
| Quintile 1 | 103/197 | ≤67.5 | 1.00 (ref) | 109/197 | ≤3.53 | 1.00 (ref) |
| Quintile 2 | 104/201 | 67.6–77.4 | 1.05 (0.79–1.41) | 104/199 | 3.54–4.06 | 1.00 (0.75–1.33) |
| Quintile 3 | 104/198 | 77.5–88.0 | 0.95 (0.71–1.27) | 95/199 | 4.07–4.50 | 0.80 (0.59–1.07) |
| Quintile 4 | 102/199 | 88.1–99.9 | 0.93 (0.69–1.25) | 91/197 | 4.51–5.06 | 0.74 (0.55–1.00) |
| Quintile 5 | 101/198 | ≥100.0 | 0.77 (0.57–1.03) | 114/198 | ≥5.07 | 0.83 (0.62–1.11) |
| Ptrend b | 0.04 | 0.17 | ||||
| per one SD c | 514/993 | 0.91 (0.83–1.00) | 513/990 | 0.94 (0.85–1.03) | ||
| CRC-specific mortality e | ||||||
| Age-, Sex-, Stage-adjusted a | ||||||
| Quintile 1 | 83/192 | ≤67.5 | 1.00 (ref) | 87/193 | ≤3.53 | 1.00 (ref) |
| Quintile 2 | 82/198 | 67.6–77.4 | 1.06 (0.76–1.47) | 78/191 | 3.54–4.06 | 0.99 (0.71–1.37) |
| Quintile 3 | 79/192 | 77.5–88.0 | 0.93 (0.67–1.30) | 70/194 | 4.07–4.50 | 0.73 (0.52–1.03) |
| Quintile 4 | 76/194 | 88.1–99.9 | 0.88 (0.63–1.23) | 69/196 | 4.51–5.06 | 0.70 (0.50–0.99) |
| Quintile 5 | 75/193 | ≥100.0 | 0.73 (0.52–1.03) | 91/192 | ≥5.07 | 0.92 (0.66–1.27) |
| Ptrend b | 0.07 | 0.48 | ||||
| per one SD c | 395/969 | 0.91 (0.81–1.01) | 395/966 | 0.96 (0.86–1.07) | ||
| Multivariable-adjusted d | ||||||
| Quintile 1 | 83/192 | ≤67.5 | 1.00 (ref) | 87/193 | ≤3.53 | 1.00 (ref) |
| Quintile 2 | 82/198 | 67.6–77.4 | 1.05 (0.76–1.46) | 78/191 | 3.54–4.06 | 1.04 (0.74–1.44) |
| Quintile 3 | 79/192 | 77.5–88.0 | 0.95 (0.68–1.32) | 70/194 | 4.07–4.50 | 0.76 (0.54–1.07) |
| Quintile 4 | 76/194 | 88.1–99.9 | 0.88 (0.63–1.24) | 69/196 | 4.51–5.06 | 0.71 (0.50–1.00) |
| Quintile 5 | 75/193 | ≥100.0 | 0.73 (0.52–1.02) | 91/192 | ≥5.07 | 0.89 (0.64–1.24) |
| Ptrend b | 0.06 | 0.39 | ||||
| per one SD c | 395/969 | 0.90 (0.81–1.00) | 395/966 | 0.95 (0.86–1.06) | ||
a Adjusted for age, sex, and stage; stratified by country. b Ptrend was calculated using the median value of each Se or SELENOP quintile included as a continuous variable, adjusted for variables in the corresponding models. c One SD = 21.99 µg/L Se; one SD = 0.96 mg/L of SELENOP. d Adjusted for age, sex, stage, smoking status, BMI, site of primary tumor, year of diagnosis, and baseline diabetes; stratified by country. e Excluded 24 cases with missing cause of death.